Clinical ink’s Post

Are you attending the MASH Drug Development Summit in Boston, September 24-26? Join Clinical ink’s David Anderson on Wednesday, September 25 as he presents a comprehensive digital platform used for remotely monitoring MASH/MASLD symptoms, determining risk of non-adherence, and providing personalized interventions to enhance adherence and retention in clinical trials. For more information on how to get MASH/MASLD data, insights, and decisions to your clinical teams faster, please contact Craig Hatton. https://lnkd.in/eQF_RzUA

We are delighted to welcome our new Chief Medical Officer, Dr. Nicholas Alp, MD PhD FACC. Dr. Alp brings more than 30 years of clinical research expertise to Clinical ink, and will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist. Read the announcement here: https://lnkd.in/eBFijFst

Did you miss our webinar? Register now to watch the recording! Many thanks to the panel for this insightful conversation about solving unmet needs in #GLP1 #cardiometabolic #clinicaltrials. Moderator: Tom Dougherty, Data Science & AI Innovative Partnership Lead at Novo Nordisk, and Panelists: Jonathan Goldman, MD MBA ATP, CEO of Clinical ink,  Kevin Dolgin, Co-Founder of Observia, Chris Bennani, Managing Director and Partner at Boston Consulting Group (BCG), Steve Polyak, Ph.D., Vice President, Engineering and Data at Clinical ink, and  David Anderson, Principal Scientist at Clinical ink Register here: https://lnkd.in/eRfdjcpH